Known targets — ChEMBL curated mechanism
ADRB1ADRB2ATP4AATP4BAXLCHRM2CHRM3DRD2FLT3HRH1HTR2AHTR2BHTR2CKCNH2KMT2AMAP2K1MAP2K2MEN1MLNRPLK4RENS1PR1SLC6A2SLC6A4atpAatpBatpCatpDatpEatpFatpFHatpGpol
The experimentally established mechanism targets of Fumaric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A known ✓ | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 known ✓ | O00255 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 4/20 | 0.90 |
| ▸ | TP53 | P04637 | 1/20 | 0.90 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.90 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.90 |
| ▸ | HCAR2 | Q8TDS4 | 4/20 | 0.50 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.44 |
| ▸ | GABRR2 | P28476 | 2/20 | 0.44 |
| ▸ | BLM | P54132 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | GABRR3 | A8MPY1 | 1/20 | 0.44 |
| ▸ | APEX1 | P27695 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Maleic Acid SCHEMBL122080 | 1.00 | TSHR (0.90) | TSHRTP53EGLN1EGLN3HCAR2 | |
| Maleic Acid SCHEMBL52799 | 1.00 | — | — | |
| Fumaric Acid SCHEMBL28080180 | 1.00 | TSHR (0.90) | TSHRTP53EGLN1EGLN3HCAR2 | |
| Fumaric Acid SCHEMBL4816794 | 1.00 | TSHR (0.90) | TSHRTP53EGLN1EGLN3HCAR2 | |
| Fumaric Acid SCHEMBL52800 | 1.00 | — | — | |
| Maleic Acid SCHEMBL4816790 | 1.00 | TSHR (0.90) | TSHRTP53EGLN1EGLN3HCAR2 | |
| Fumaric Acid SCHEMBL6468133 | 1.00 | TSHR (0.90) | TSHRTP53EGLN1EGLN3HCAR2 | |
| Fumaric Acid SCHEMBL106605 | 1.00 | — | — | |
| Maleic Acid SCHEMBL7102604 | 0.95 | TSHR (0.82) | TSHRTP53EGLN1EGLN3HCAR2 | |
| Maleic Acid SCHEMBL3410757 | 0.95 | TSHR (0.82) | TSHRTP53EGLN1EGLN3HCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1363 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4659850-A2 | IMPROVED PROTEIN RECOVERY | Bristol-Myers Squibb Company (US) | 2025-12-10 | — | — | EP | claimed |
| EP-3837273-B1 | IMPROVED PROTEIN RECOVERY | BRISTOL MYERS SQUIBB CO (US) | 2025-09-24 | — | — | EP | claimed |
| US-20250127776-A1 | ORAL PHARMACEUTICAL COMPOSITION | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2025-04-24 | — | — | US | claimed |
| US-20250092090-A1 | PROTEIN RECOVERY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-03-20 | — | — | US | claimed |
| CN-118325107-B | Mechanochemical method for preparing fumaric acid-based metal-organic framework material | 广东碳语新材料有限公司 | 2025-02-28 | — | — | CN | claimed |
| CN-119438283-A | Detection of cancer cell death by deuterium labeled fumaric acid or salt thereof | 深圳鼎邦生物科技有限公司 | 2025-02-14 | — | — | CN | claimed |
| US-12103949-B2 | Protein recovery | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-10-01 | — | — | US | claimed |
| CN-118634360-A | Negative divalent or negative trivalent anion salt crosslinked frozen gel and preparation method and application thereof | 四川大学 | 2024-09-13 | — | — | CN | claimed |
| CN-118638334-A | Asymmetric bacterial cellulose membrane with antibacterial function and preparation method and application thereof | 理工清科(重庆)先进材料研究院有限公司 | 2024-09-13 | — | — | CN | claimed |
| CN-118373647-A | Ion erosion resistant self-repairing marine concrete and preparation method thereof | 长安大学 | 2024-07-23 | — | — | CN | claimed |
| US-20050135993-A1 | Manganese oxide based materials as ion intercalation hosts in lithium batteries | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2005-06-23 | — | — | US | claimed |
| US-20040132689-A1 | Aqueous preparation containing a shark-derived chondroitin iron sulfate colloid | NIPRO CORPORATION (JP) | 2004-07-08 | — | — | US | claimed |
| EP-1433482-A1 | Aqueous preparation containing a shark-derived chondroitin iron sulfate colloid | Nipro Corporation (JP) | 2004-06-30 | — | — | EP | claimed |
| CN-1267335-A | Diagnostic method and kits for evaluation of sympathetic nervous system function | NEURO BIOTECH INC (CA) | 2000-09-20 | — | — | CN | claimed |
| WO-2000029604-A1 | PRODUCTION OF BIOLOGICAL MATERIALS BY SIMULTANEOUS AEROBIC AND ANAEROBIC RESPIRATION | THE UNIVERSITY OF AKRON (US) | 2000-05-25 | — | — | WO | claimed |
| EP-0991776-A1 | DIAGNOSTIC METHODS AND KITS FOR THE EVALUATION OF THE SYMPATHETIC NERVOUS SYSTEM FUNCTION | NEURO-BIOTECH INC. (CA) | 2000-04-12 | — | — | EP | claimed |
| US-5879902-A | Diagnostic methods and kits for the evaluation of the sympathetic nervous system function | NEURO-BIOTECH INC. (CA) | 1999-03-09 | — | — | US | claimed |
| WO-1998058076-A1 | DIAGNOSTIC METHODS AND KITS FOR THE EVALUATION OF THE SYMPATHETIC NERVOUS SYSTEM FUNCTION | NEURO-BIOTECH INC. (CA) | 1998-12-23 | — | — | WO | claimed |
| US-5821030-A | DIRECT DIGITAL EXPOSURE; HIGH WRITING SPEED; ADHESION; ANTIFOGGING AGENTS; SHELF LIFE; USING A POLYCARBOXYLIC ACID IN THE PHOTOPOLYMERIZATION INITIATOR SYSTEM AND A BASIC COMPOUND IN THE OXYGEN BARRIER LAYER | KODAK POLYCHROME GRAPHICS (US) | 1998-10-13 | — | — | US | claimed |
| US-5575899-A | ELECTROLYSIS OF A SOLUTION OF ZINC CHLORIDE, NICKEL CHLORIDE AND POTASSIUM CHLORIDE, NONIONIC SURFACTANT WITH NICOTINIC ACID, UREA, THIOUREA, NICOTINAMIDE, THIOGLYCOLIC ACID AND SODIUM THIOSULFATE | KAWASAKI STEEL CORPORATION (JP) | 1996-11-19 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250127776-A1 | ORAL PHARMACEUTICAL COMPOSITION | LIPA, CYP2C19, PNLIP | KMT2A 4828/4885MEN1 1675/4885TSHR 3925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.